• Explore /
  • Poster
  • / Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or <em>de novo </em>mHSPC (M1 at diagnosis): <em>Post hoc</em> analysis of the phase 3 ARCHES trial.

Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial.

Abstract Video & Slides Poster

Authors

Andrew Armstrong

Andrew J. Armstrong

Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC

Andrew J. Armstrong , Taro Iguchi , Arun Azad , Russell Zelig Szmulewitz , Jeffrey Holzbeierlein , Arnauld Villers , Antonio Alcaraz , Boris Alexeev , Neal D. Shore , Francisco Gomez-Veiga , Brad Rosbrook , Fabian Zohren , Shunsuke Yamada , Gabriel P. Haas , Arnulf Stenzl

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 115)

DOI

10.1200/JCO.2022.40.6_suppl.115

Abstract #

115

Poster Bd #

F7

Abstract Disclosures

Similar Posters

First Author: Arun Azad

First Author: Arun Azad

First Author: Andrew J. Armstrong

First Author: Neal D. Shore